Published in Pharma Investments, Ventures and Law Weekly, August 9th, 2009
"Due to its design and the high level of required premiums, the program is unlikely to cover more than a very small proportion of the intended population," said Eric Stallard, the chairperson...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.